Saol Announces FDA Approval of LYVISPAHTM and Divesture
https://dfwcapital.com/saol-announces-fda-approval-of-lyvispahtm-and-divesture/
WEBDec 28, 2021 · ROSWELL, GA US/Dublin, IE/Hamilton, BM Dec. 6, 2021 – Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saol’s LYVISPAH™ (baclofen) oral granules. LYVISPAH™ (lye-vis’-pah) is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for …
DA: 13 PA: 67 MOZ Rank: 4